BETA

13 Amendments of Dominique RIQUET related to 2017/2254(INI)

Amendment 25 #
Draft opinion
Recital C a (new)
Ca. whereas the Commission has committed to invest more than EUR 200 million in AMR for the last 3 years of Horizon 2020;
2018/01/18
Committee: ITRE
Amendment 36 #
Draft opinion
Paragraph 1 a (new)
1a. Urges the need to enable antimicrobial stewardship in order to improve evidence-based prescribing;
2018/01/18
Committee: ITRE
Amendment 44 #
Draft opinion
Paragraph 1 c (new)
1c. Underlines the need to invest in research and innovation dedicated to improvement of vaccination in order to support prevention;
2018/01/18
Committee: ITRE
Amendment 49 #
Draft opinion
Paragraph 2 – subparagraph 1 (new)
Considers that the pull models can exist of, but are not limited to the following models: - Transferable Market Exclusivities (TME):TMEs are a type of pull mechanisms that grants the new antibiotic market additional months of additional market exclusivity that can be transferred to another compound with a better commercial opportunity. This model could only work under the following conditions: defined length of the extension of exclusivity; distribute exclusivity amongst diverse compounds and each compound can only benefit from a TME once; sufficient notice: public disclosure of target compound for TME utilisation; - Lump sum Market Entry Reward (MER):increasing the revenue of new antimicrobials by directly through a cash payment upon market entry. These lump sum payment model could only work if the following conditions are met: scientifically sound criteria for entitlement to a reward, basing eligibility criteria on lists issued by the WHO or other relevant bodies; a pre-defined maximum number of rewards for priority pathogen and/or target product profile, defined by relevant organisations based on current and future medical need; - National or personal insurance model: as part of national or personal health insurance, citizens can ensure the access and development of new antimicrobials;
2018/01/18
Committee: ITRE
Amendment 53 #
Draft opinion
Paragraph 2 a (new)
2a. Underlines the importance of identifying and addressing specific access, market sustainability and supply bottlenecks for existing antibiotics, diagnostics and vaccines, and the development of innovative financing and procurement mechanisms to resolve them;
2018/01/18
Committee: ITRE
Amendment 67 #
Draft opinion
Paragraph 3 a (new)
3a. Underlines the importance of improvement and dedication of Public Private Partnerships and collaborations between industry, SMEs and public researchers to overcome the scientific challenges of creating new antibiotics, vaccines and diagnostics;
2018/01/18
Committee: ITRE
Amendment 70 #
Draft opinion
Paragraph 3 b (new)
3b. Urges the Commission to develop a mission on AMR in the future FP9 with a cross-sectorial and interdisciplinary approach;
2018/01/18
Committee: ITRE
Amendment 75 #
Draft opinion
Paragraph 4 a (new)
4a. Emphasises the need to analyse big data coming from different industry sectors;
2018/01/18
Committee: ITRE
Amendment 77 #
Draft opinion
Paragraph 4 b (new)
4b. Highlights the importance of environmental data in order to have an overview of all aspects affecting AMR;
2018/01/18
Committee: ITRE
Amendment 78 #
Draft opinion
Paragraph 4 c (new)
4c. Underlines the lack of collection of data on the impact on health and socioeconomic burden of AMR on an EU- level and global scale;
2018/01/18
Committee: ITRE
Amendment 79 #
Draft opinion
Paragraph 4 d (new)
4d. Asks the Member States to improve and enable the access to personalized care of patients;
2018/01/18
Committee: ITRE
Amendment 85 #
Draft opinion
Paragraph 5 a (new)
5a. Calls upon the G7, G20 and BRICS to act and work in close collaboration;
2018/01/18
Committee: ITRE
Amendment 86 #
5b. Urges to scale up and combine the numerous international programmes on EU and international level in order to facilitate and support the programmes of European Antimicrobial Resistance Network (EARS-Net), European Surveillance of Antimicrobial Consumption Network (ESAC-Net), Central Asian and Eastern European Surveillance of Antimicrobial Resistance (CAESAR), Joint Interagency Antimicrobial Consumption and Resistance Analysis (JIACRA), ), Institutional Programme for the Prevention and Control of Healthcare Associated Infections and Appropriate Use of Antimicrobials (PIRASAO), WHO Antimicrobial Medicines Consumption Network (AMC), European & Developing Countries Clinical Trials Partnership(EDCTP) and Poverty Related and Neglected Diseases (PRND)1a; _________________ 1a Damage done by Poverty Related and Neglected Diseases within the EU in the year 2015: almost 10.000 Deaths in the EU, 30.000 new HIV infections, mosquito transmitting dengue and chikungunya reported in many parts of Europe. Cf. Global Burden of Disease Results Tool, WHO and European Centre for Disease Prevention and Control.
2018/01/18
Committee: ITRE